bioRxiv ScienceSearch

Biology subjects

Alexander G Fletcher

Publications and source records attributed to Alexander G Fletcher.

4 recordsLinked to original sources

A hierarchical Bayesian framework for understanding the spatiotemporal dynamics of the intestinal epithelium

Our work addresses two key challenges, one biological and one methodological. First, we aim to understand how proliferation and cellular migration rates in the intestinal epithelium are related under healthy, damaged (Ara-C treated) and recovering conditions, and how these relations can be used to identify mechanisms of repair and regeneration. We analyse new data, presented in more detail in a companion paper, in which BrdU/IdU cell-labelling experiments were performed under these respective conditions. Second, in considering how to more rigorously process these data and interpret them using mathematical models, we develop a probabilistic, hierarchical framework. This framework provides a best-practice approach for systematically modelling and understanding the uncertainties that can otherwise undermine drawing reliable conclusions - uncertainties in experimental measurement and treatment, difficult-to-compare mathematical models of underlying mechanisms, and unknown or unobserved parameters. Both discrete and continuous mechanistic models are considered and related via hierarchical conditional probability assumptions. This allows the incorporation of features of both continuum tissue models and discrete cellular models. We perform model checks on both in-sample and out-of-sample datasets and use these checks to illustrate how to test possible model improvements and assess the robustness of our conclusions. This allows us to consider - and ultimately decide against - the need to retain finite-cell-size effects to explain a small misfit appearing in one set of long-time, out-of-sample predictions. Our approach leads us to conclude, for the present set of experiments, that a primarily proliferation-driven model is adequate for predictions over most time-scales. We describe each stage of our framework in detail, and hope that the present work may also serve as a guide for other applications of the hierarchical approach to problems in computational and systems biology more generally.\n\nAuthor SummaryThe intestinal epithelium serves as an important model system for studying the dynamics and regulation of multicellular populations. It is characterised by rapid rates of self-renewal and repair; failure of the regulation of these processes is thought to explain, in part, why many tumours occur in the intestinal and similar epithelial tissues. These features have led to a large amount of work on estimating rate parameters in the intestine. There still remain, however, large gaps between the raw data collected, the experimental interpretation of these data, and speculative mechanistic models for underlying processes. In our view hierarchical statistical modelling provides an ideal, but currently underutilised, method to begin to bridge these gaps. This approach makes essential use of the distinction between measurement, process and parameter models, giving an explicit framework for combining experimental data and mechanistic modelling in the presence of multiple sources of uncertainty. As we illustrate, the hierarchical approach also provides a suitable framework for addressing other methodological questions of broader interest in systems biology: how to systematically relate discrete and continuous mechanistic models; how to formally interpret and visualise statistical evidence; and how to express causal assumptions in terms of conditional independence.

Systems Biology

A computational modelling approach for deriving biomarkers to predict cancer risk in premalignant disease

The lack of effective biomarkers for predicting cancer risk in premalignant disease is a major clinical problem. There is a near-limitless list of candidate biomarkers and it remains unclear how best to sample the tissue in space and time. Practical constraints mean that only a few of these candidate biomarker strategies can be evaluated empirically and there is no framework to determine which of the plethora of possibilities is the most promising. Here we have sought to solve this problem by developing a theoretical platform for in silico biomarker development. We construct a simple computational model of carcinogenesis in premalignant disease and use the model to evaluate an extensive list of tissue sampling strategies and different molecular measures of these samples. Our model predicts that: (i) taking more biopsies improves prognostication, but with diminishing returns for each additional biopsy; (ii) longitudinally-collected biopsies provide slightly more prognostic information than a single biopsy collected at the latest possible time-point; (iii) measurements of clonal diversity are more prognostic than measurements of the presence or absence of a particular abnormality and are particularly robust to confounding by tissue sampling; and (iv) the spatial pattern of clonal expansions is a particularly prognostic measure. This study demonstrates how the use of a mechanistic framework provided by computational modelling can diminish empirical constraints on biomarker development.

Cancer Biology

Exploiting evolutionary non-commutativity to prevent the emergence of bacterial antibiotic resistance

The increasing rate of antibiotic resistance and slowing discovery of novel antibiotic treatments presents a growing threat to public health. Here, we develop a Markov Chain model of evolution in asexually reproducing populations which is an encoding of the Strong Selection Weak Mutation model of evolution on fitness landscapes. This model associates the global properties of the fitness landscape with the algebraic properties of the Markov Chain transition matrix and allows us to derive general results on the non-commutativity and irreversibility of natural selection as well as antibiotic cycling strategies. Utilizing this formalism, we analyse 15 empirical fitness landscapes of E. coli under selection by di.erent beta-lactam antibiotics and demonstrate that the emergence of resistance to a given antibiotic can be both hindered and promoted by di.erent sequences of drug application. Further, we derive optimal drug application sequences with which we can probabilistically steer the population through genotype space to avoid the emergence of resistance. This suggests a new strategy in the war against antibiotic.therapy.resistant organisms: drug sequencing to shepherd evolution through genotype space to states from which resistance cannot emerge and by which to maximize the chance of successful therapy. BackgroundThe increasing rate of antibiotic resistance and slowing discovery of novel antibiotic treatments presents a growing threat to public health. Previous studies of bacterial evolutionary dynamics have shown that populations evolving on fitness landscapes follow predictable paths. In this article, we develop a general mathematical model of evolution and hypothesise that it can be used to understand, and avoid, the emergence of antibiotic resistance. Methods and FindingsWe develop a Markov Chain model of evolution in asexually reproducing populations which is an encoding of the Strong Selection Weak Mutation model of evolution on fitness landscapes. This model associates the global properties of the fitness landscape with the algebraic properties of the Markov Chain transition matrix and allows us to derive general results on the non-commutativity and irreversibility of natural selection as well as antibiotic cycling strategies. Utilizing this formalism, we analyse 15 empirical fitness landscapes of E. coli under selection by different {beta}-lactam antibiotics and demonstrate that the emergence of resistance to a given antibiotic can be both hindered and promoted by different sequences of drug application. We show that resistance to a given antibiotic is promoted in 61.4%, 68.6% and 70.3% of possible orderings of single, pair or triple prior drug administrations, respectively. Further, we derive optimal drug application sequences with which we can probabilistically steer the population through genotype space to avoid the emergence of resistance. ConclusionsOur model provides generalisable results of interest to theorists studying evolution as well as providing specific, testable predictions for experimentalists to validate our methods. Further, these results suggest a new strategy in the war against antibiotic-therapy-resistant organisms: drug sequencing to shepherd an evolving population through genotype space to states from which resistance cannot emerge and from which we can maximize the likelihood of successful therapy using existing drugs. While our results are derived using a specific class of antibiotics, the method is generalisable to other situations, including the emergence of resistance to targeted therapy in cancer and how species could change secondary to changing climate or geographical movement.

Evolutionary Biology

A filter-flow perspective of hematogenous metastasis offers a non-genetic paradigm for personalized cancer therapy

Translational RelevanceSince the discovery of circulating tumor cells (CTC), we have struggled for ways to use them to inform treatment. The only currently accepted method for this is a more is worse paradigm by which clinicians measure CTC burden before and after treatment to assess efficacy. Research efforts are currently focused almost entirely on genetic classification of these cells, which has yet to bear any fruit translationally. We suggest that we should shift the focus of our investigation to one driven by a physical sciences perspective. Specifically, by understanding the vascular system as a network of interconnected organs and capillary beds as filters that capture CTCs. By ascertaining the distribution of CTCs in this network for individual patients, information about the existence of subclinical metastatic disease, and therefore metastatic propensity, will come to light, and allow for better staging, prognostication and rational use of organ-directed therapy in the setting of oligometastatic disease.\n\nAbstractO_ST_ABSPurposeC_ST_ABSResearch into mechanisms of hematogenous metastasis has largely become genetic in focus, attempting to understand the molecular basis of seed-soil relationships. However, preceding this biological mechanism is the physical process of dissemination of circulating tumour cells (CTCs) in the circulatory network. We utilize a novel, network perspective of hematogenous metastasis and a large dataset on metastatic patterns to shed new light on this process.\n\nExperimental DesignThe metastatic efficiency index (MEI), previously suggested by Weiss, quantifies the process of hematogenous metastasis by taking the ratio of metastatic incidence for a given primary-target organ pair and the relative blood flow between the two sites. In this paper we extend the methodology by taking into account the reduction in CTC number that occurs in capillary beds and a novel network model of CTC flow.\n\nResultsBy applying this model to a dataset of metastatic incidence, we show that the MEI depends strongly on the assumptions of micrometastatic lesions in the lung and liver. Utilizing this framework we can represent different configurations of metastatic disease and offer a rational method for identifying patients with oligometastatic disease for inclusion in future trials.\n\nConclusionsWe show that our understanding of the dynamics of CTC flow is significantly lacking, and that this specifically precludes our ability to predict metastatic patterns in individual patients. Our formalism suggests an opportunity to go a step further in metastatic disease characterization by including the distribution of CTCs at staging, offering a rational method of trial design for oligometastatic disease.

Cancer Biology